Rabu, 11 September 2013

FACTS THAT YOU NEED TO KNOW ABOUT DELIRIUM




Introduction
Definition : Disturbance of consciousness and a change in cognition that develop over a short time.

It is a syndrome, not a disease.

Has many causes.

Classically, delirium has a sudden onset (hours or days), a brief fluctuating course, and a rapid improvement when the causative factors is identified and eliminated.
Epidemiology 
Prevalence – 0.4% age >18, 1.1% age >55 
10-30% of medically ill patients who are hospitalized. 
30% of patients in surgical and cardiac ICU. 
30-40% of patients with acquired immune deficiency syndrome who are hospitalize. 
80% of terminally ill patients. 
Risk Factor
Advanced age (30-40% hospitalize patients age > 65 years old) 
Nursing home residents (60% age >75 years old) 
Other predisposing factors - preexisting brain damage (eg: cerebrovascular disease, tumor), history of delirium, alcohol dependence, diabetes, cancer and malnutrition. 
Male 
Etiology
Major causes: 
central nervous system disease (eg: epilepsy) 
systemic disease (eg: cardiac failure) 
Intoxication/withdrawal from pharmacological or toxic agents 
*clinicians should assume that any drug that a patient has taken may be the cause of delirium  
 Clinical Features
 
Diagnosis
1.Delirium due to a general medical condition 
2.Substance intoxication delirium 
3.Substance withdrawal delirium 
4.Delirium due to multiple etiologies 
5.Delirium not otherwise specified 
Course and Prognosis
Symptoms usually persist as long as the causally relevant factors are present 
Generally, delirium lasts less than a week 
Symptoms usually recede over a 3 to 7 day period, after removal of causative factors 
Some symptoms may take up to 2 weeks to resolve 
The occurrence of delirium is associated with a high mortality rate in the ensuing year 
Periods of delirium are sometimes followed by depression or PTSD
 Treatment
Primary goal: treat underlying cause 
Physical support to prevent accidents 
Pharmacotherapy 
    i.Psychosis 
      •Haloperidol 2 to 6 mg IM 
      •2nd generation anti-psychotics 
  ii.Insomnia 
      •BDZ with short/intermediate half-lives (e.g lorazepam 1 to 2 mg at bedtime) BDZ with long half-lives should be avoided unless as part of treatment for underlying disorder

Tiada ulasan:

Catat Ulasan